PBS is financially sustainable, says Medicines Australia as price cuts announced

17 December 2013
medaustralia-big

The Australian Government’s Mid Year Economic and Fiscal Outlook proves that the Pharmaceutical Benefits Scheme (PBS) is financially sustainable, claims trade group Medicines Australia.

The MYEFO report aims to assess the Government's fiscal performance against the fiscal strategy set out in the current budget papers. It updates key information contained in the most recent budget economic and fiscal outlook report and contains a detailed statement of tax expenditures, presenting disaggregated information on tax expenditures.

The MYEFO released today shows that the PBS is a major parameter saving in the budget, with spending in 2013-14 to be A$526 million lower than budgeted just seven months ago, equivalent to an additional A$2.7 billion in savings over the next four years.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical